Exelixis | EXEL - سود عملیاتی





سود عملیاتی تغییر دادن تاریخ
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Akebia Therapeutics USD 13.51M 27.82M 2025-03
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bayer EUR 1.11B 1.65B 2025-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Eisai JPY 20.03B 6.36B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Exelixis USD 235.91M 20.45M 2025-12
Genmab DKK 360M 172M 2025-06
Glaxosmithkline GBP 3.76B 1.32B 2025-09
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
MacroGenics USD 18.64M 55.4M 2025-09
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.5B 363M 2025-09
Pfizer USD 4.65B 3.99B 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sanofi EUR 1.5B 2.29B 2025-12
Takeda JPY 168.82B 479.89B 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Xencor USD -53.63M 6.11M 2025-12